Indianapolis, Indiana, and Boston, Massachusetts, United States, October 14, 2026
Genezen and Galibra Neuroscience have announced a manufacturing partnership to advance GAL005, an investigational adeno-associated virus (AAV)-based gene therapy for succinic semialdehyde dehydrogenase (SSADH) deficiency, a rare inherited neurological and metabolic disorder. Under the agreement, Genezen will manufacture material for investigational new drug (IND)-enabling toxicology and biodistribution studies and produce clinical-grade material under current Good Manufacturing Practice (cGMP) standards for a planned Phase 1 clinical trial. The collaboration represents an important step toward evaluating the experimental treatment in humans. GAL005 is designed to deliver a functional copy of the ALDH5A1 gene, addressing the genetic defect responsible for SSADH deficiency. Galibra has reported encouraging preclinical findings, including improved brain chemistry and reversal of disease symptoms in treated animal models. The program has also received Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA). However, the therapy remains investigational, and its safety and effectiveness in humans have not yet been established.
GAL005 Targets the Genetic Cause of SSADH Deficiency
SSADH deficiency is a rare inherited disorder caused by mutations in the ALDH5A1 gene, which encodes the enzyme succinic semialdehyde dehydrogenase. This enzyme plays an essential role in the metabolism of gamma-aminobutyric acid (GABA), a neurotransmitter involved in regulating communication between nerve cells in the central nervous system. When the enzyme does not function properly, the body cannot efficiently process certain metabolites in the GABA degradation pathway. The resulting biochemical imbalance can affect neurological development and function. Children with SSADH deficiency may experience developmental delays, impaired speech, low muscle tone, behavioral difficulties and seizures. Symptoms and disease severity can vary among affected individuals. There are currently no approved therapies that directly address the underlying genetic cause of the disorder, highlighting the need for disease-modifying treatment strategies. GAL005 is being developed as a potential one-time gene replacement therapy intended to restore the function of the missing or deficient enzyme. The approach aims to introduce a working copy of ALDH5A1 into relevant cells, enabling them to produce the SSADH enzyme and potentially improve the metabolic abnormalities associated with the disease. The program builds on preclinical research conducted by scientists at Boston Children’s Hospital and supported by the SSADH Association. Galibra Neuroscience was co-founded by researchers Alexander Rotenberg and Henry Lee, whose work helped advance the gene therapy concept toward development.
AAV Technology Designed to Cross the Blood-Brain Barrier
A key feature of GAL005 is its use of CapX, an engineered AAV capsid developed by Apertura Gene Therapy. AAV vectors are widely investigated as delivery systems for gene therapies because they can transport genetic material into target cells. GAL005 is designed for intravenous administration, with CapX engineered to bind to human transferrin receptor 1 (hTfR1). This receptor-targeting approach is intended to help the vector cross the blood-brain barrier, a protective structure that restricts the movement of many substances from the bloodstream into the central nervous system. Delivering a therapeutic gene to the brain is a major challenge in treating inherited neurological disorders. The CapX approach is intended to improve access to relevant central nervous system cells, where restoration of SSADH activity could potentially address the disease’s underlying biochemical disturbance. In preclinical studies, Galibra reported that treatment of SSADH knockout mice resulted in normalization of brain chemistry, reversal of disease symptoms and survival in all treated animals. These findings provide a scientific rationale for further investigation, but results from animal models do not necessarily predict outcomes in humans. The next development stages will require appropriate toxicology testing, biodistribution assessments, manufacturing controls and regulatory review before a first-in-human trial can begin.
Advertisement
Genezen Manufacturing Supports Planned Phase 1 Trial
Under the partnership, Genezen will support GAL005 manufacturing at its Indianapolis facility. The company specializes in the development and manufacturing of viral vectors for gene and cell therapies. Its responsibilities will include supplying material for nonclinical studies and producing cGMP clinical material intended for the planned Phase 1 trial. Establishing a consistent and well-characterized manufacturing process is essential for gene therapy development. Product quality, identity, purity, potency and safety must be evaluated through appropriate analytical methods to support regulatory submissions and clinical use. Genezen plans to apply its AAV manufacturing platform and analytical capabilities to establish a process suitable for GAL005’s investigational development requirements. The partnership is intended to support Galibra as it progresses through IND-enabling activities and prepares for clinical testing. The program also reflects the contribution of patient advocacy organizations to rare-disease research. Brad and Carolyn Hoffman founded the SSADH Association after their son was diagnosed with the condition in 1998. The organization has supported research initiatives, including natural history studies, patient-derived stem cell resources and preclinical gene therapy investigations. For the rare-disease community, the manufacturing agreement represents progress toward clinical evaluation of a potential disease-modifying treatment. The planned Phase 1 trial will be an important milestone in assessing safety and tolerability in humans, with further studies required to determine whether GAL005 can provide meaningful clinical benefits.
Source: Genezen, Galibra Neuroscience press release
